Ad
related to: list of atorvastatin side effects for men"Shop around for the best prices without a membership fee." - Today
Search results
Results from the WOW.Com Content Network
Atorvastatin is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. [4] For the prevention of cardiovascular disease, statins are a first-line treatment. [4] It is taken by mouth. [4] Common side effects include joint pain, diarrhea, heartburn, nausea, and muscle pains. [4]
Case in point — 30 to 50 percent of men experience male pattern baldness by age 50. ... We’ll save you the trouble of looking up if statins cause hair loss or something like “atorvastatin ...
The class is on the World Health Organization's List of Essential Medicines with simvastatin being the listed medicine. [10] In 2005, sales were estimated at US$18.7 billion in the United States. [11] The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. [12]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Data from the Cholesterol Treatment Trialists’ (CTT) publication [10] was used to determine the effects of fluvastatin, atorvastatin and rosuvastatin on LDL cholesterol lowering and reduction of myocardial infarction. In two RCTs an average dose of 72 mg/day fluvastatin reduced LDL cholesterol by 31.9%, and reduced myocardial infarction ...
This is a list of drugs and substances that are known or suspected to cause Stevens–Johnson syndrome This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources .
Research conducted by Indiana University's Center for Sexual Health showed that using lube makes it 50% easier for both men and women to orgasm. And it makes sense, too: according to Elist, lube ...
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.